Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genvir (Flamel Technologies).

D L Barnard1

  • 1Utah State University, Institute for Antiviral Research, Logan 84322-5600, USA. honery@cc.usu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|September 25, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo influenza virus-inhibitory effects of viramidine.

Antiviral research·2005
Same author

Antiviral research - 13th International Conference.

IDrugs : the investigational drugs journal·2005
Same author

Antiviral Research - 15th International Conference. Mega-HAART and tenofovir. 17-21 March 2002, Prague, Czech Republic.

IDrugs : the investigational drugs journal·2004
Same author

In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.

Antimicrobial agents and chemotherapy·2004
Same author

Fulminant Crohn's colitis after allogeneic stem cell transplantation.

Gut·2003
Same author

Pulmonary complications following bone marrow transplantation.

The British journal of radiology·2003
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Genvir, a controlled-release aciclovir formulation, shows comparable efficacy to existing herpes treatments. Developed by Flamel Technologies, it uses Micropump technology for extended absorption, with Phase III trials completed.

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Virology

Background:

  • Herpes simplex virus (HSV) and varicella zoster virus (VZV) infections require effective antiviral treatments.
  • Existing therapies like valaciclovir and famciclovir have established efficacy.
  • Controlled-release formulations aim to improve patient compliance and therapeutic outcomes.

Purpose of the Study:

  • To evaluate the development of Genvir, a novel controlled-release formulation of aciclovir.
  • To assess the therapeutic potential of Genvir for HSV and VZV infections.
  • To highlight the application of Flamel's Micropump technology in antiviral drug delivery.

Main Methods:

  • Development of Genvir, a twice-daily controlled-release formulation of aciclovir.
  • Utilizing Flamel's proprietary Micropump microparticle-based drug delivery technology.

Related Experiment Videos

  • Conducting Phase III clinical trials to assess efficacy and safety.

    • Main Results:

    • Genvir demonstrated comparable therapeutic efficacy to valaciclovir and famciclovir.
    • Phase III trials for Genvir have been successfully completed.
    • The Micropump technology facilitates extended drug absorption in the small intestine.

    Conclusions:

    • Genvir represents a promising new treatment option for herpes simplex virus and varicella zoster virus infections.
    • The controlled-release formulation and Micropump technology offer potential advantages in antiviral therapy.
    • Regulatory submissions are underway in Europe, with plans for US clinical trials.